{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T08:51:11Z","timestamp":1780476671314,"version":"3.54.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.medcli.2019.07.026","type":"journal-article","created":{"date-parts":[[2019,11,23]],"date-time":"2019-11-23T16:24:25Z","timestamp":1574526265000},"page":"101-107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Riesgo de infecci\u00f3n asociada a nuevas terapias para el tratamiento de los s\u00edndromes linfoproliferativos"],"prefix":"10.1016","volume":"154","author":[{"given":"Ibai","family":"Los-Arcos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9838-1950","authenticated-orcid":false,"given":"Juan","family":"Aguilar-Company","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Ruiz-Camps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2019.07.026_bib0190","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/ajh.24282","article-title":"Chronic lymphocytic leukemia (CLL)-Then and now","volume":"91","author":"Rai","year":"2016","journal-title":"Am J Hematol."},{"key":"10.1016\/j.medcli.2019.07.026_bib0195","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2002-04-1258","article-title":"Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 CALGB 9712","volume":"101","author":"Byrd","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2019.07.026_bib0200","first-page":"1","article-title":"Invasive fungal infections in patients with chronic lymphoproliferative disorders in the era of target drugs","volume":"10","author":"Facchinelli","year":"2018","journal-title":"Mediterr J Hematol Infect Dis."},{"key":"10.1016\/j.medcli.2019.07.026_bib0205","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1741-7015-9-36","article-title":"Risk of infection in patients with lymphoma receiving rituximab: Systematic review and meta-analysis","volume":"9","author":"Lanini","year":"2011","journal-title":"BMC Med."},{"key":"10.1016\/j.medcli.2019.07.026_bib0210","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.cmi.2018.02.003","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)","volume":"24","author":"Ippolito","year":"2018","journal-title":"Clin Microbiol Infect."},{"key":"10.1016\/j.medcli.2019.07.026_bib0215","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/annonc\/mdq583","article-title":"Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: Meta-analysis and examination of FDA safety reports","volume":"22","author":"Evens","year":"2011","journal-title":"Ann Oncol."},{"key":"10.1016\/j.medcli.2019.07.026_bib0220","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.blre.2018.03.004","article-title":"Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections","volume":"32","author":"Hilal","year":"2018","journal-title":"Blood Rev."},{"key":"10.1016\/j.medcli.2019.07.026_bib0225","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"Executive summary: 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.medcli.2019.07.026_bib0230","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.medcli.2018.05.008","article-title":"Vacunas para pacientes en tratamiento con f\u00e1rmacos inmunodepresores, inmunomoduladores o biol\u00f3gicos","volume":"151","author":"Peremiquel-Trillas","year":"2018","journal-title":"Med Clin (Barc)."},{"key":"10.1016\/j.medcli.2019.07.026_bib0235","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41375-019-0388-x","article-title":"Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL)","volume":"33","author":"Maschmeyer","year":"2019","journal-title":"Leukemia."},{"key":"10.1016\/j.medcli.2019.07.026_bib0240","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1086\/504811","article-title":"Infectious complications associated with alemtuzumab use for lymphoproliferative disorders","volume":"43","author":"Martin","year":"2006","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.medcli.2019.07.026_bib0245","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s40265-018-1003-6","article-title":"Targeting Bruton's tyrosine kinase across B-cell malignancies","volume":"78","author":"Da Cunha-Bang","year":"2018","journal-title":"Drugs."},{"key":"10.1016\/j.medcli.2019.07.026_bib0250","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.cmi.2018.02.009","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors)","volume":"24","author":"Reinwald","year":"2018","journal-title":"Clin Microbiol Infect."},{"key":"10.1016\/j.medcli.2019.07.026_bib0255","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.blre.2018.04.007","article-title":"Infections in patients with chronic lymphocytic leukaemia: Mitigating risk in the era of targeted therapies","volume":"32","author":"Teh","year":"2018","journal-title":"Blood Rev."},{"key":"10.1016\/j.medcli.2019.07.026_bib0260","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/cid\/ciy175","article-title":"Serious infections in patients receiving ibrutinib for treatment of lymphoid cancer","volume":"67","author":"Varughese","year":"2018","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.medcli.2019.07.026_bib0265","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1182\/blood-2017-12-823393","article-title":"Ibrutinib blocks Btk-dependent NF-?B and NFAT responses in human macrophages during Aspergillus fumigatus phagocytosis","volume":"132","author":"Bercusson","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2019.07.026_bib0270","unstructured":"Ibrutinib: Summary of product characteristics s. f."},{"key":"10.1016\/j.medcli.2019.07.026_bib0275","first-page":"1","article-title":"Isavuconazole for the treatment of invasive fungal disease in patients receiving ibrutinib","author":"Cummins","year":"2018","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.medcli.2019.07.026_bib0280","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2019.07.026_bib0285","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): A single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet."},{"key":"10.1016\/j.medcli.2019.07.026_bib0290","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/hon.2540","article-title":"Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper","volume":"37","author":"Cuneo","year":"2019","journal-title":"Hematol Oncol."},{"key":"10.1016\/j.medcli.2019.07.026_bib0295","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1182\/blood-2017-06-788133","article-title":"Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy","volume":"131","author":"Coutre","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2019.07.026_bib0300","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1200\/JCO.2017.76.6840","article-title":"Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: Results from the full population of a phase ii pivotal trial","volume":"36","author":"Stilgenbauer","year":"2018","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2019.07.026_bib0305","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40264-018-0773-9","article-title":"Safety and tolerability of histone deacetylase (HDAC) inhibitors in oncology","volume":"42","author":"Shah","year":"2019","journal-title":"Drug Saf."},{"key":"10.1016\/j.medcli.2019.07.026_bib0310","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1182\/blood-2015-02-567453","article-title":"Immune checkpoint blockade in hematologic malignancies","volume":"125","author":"Armand","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2019.07.026_bib0315","first-page":"17","article-title":"Checkpoint inhibitors and other immune therapies for Hodgkin and non-Hodgkin lymphoma","author":"Matsuki","year":"2016","journal-title":"Curr Treat Options Oncol."},{"key":"10.1016\/j.medcli.2019.07.026_bib0320","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1093\/cid\/ciw539","article-title":"The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma","volume":"63","author":"Del Castillo","year":"2016","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.medcli.2019.07.026_bib0325","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/CJI.0000000000000081","article-title":"Autoimmune colitis and subsequent CMV-induced hepatitis after treatment with ipilimumab","volume":"38","author":"Uslu","year":"2015","journal-title":"J Immunother."},{"key":"10.1016\/j.medcli.2019.07.026_bib0330","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1016\/j.jtho.2016.07.006","article-title":"Anti-PD1 antibody treatment and the development of acute pulmonary tuberculosis","volume":"11","author":"Fujita","year":"2016","journal-title":"J Thorac Oncol."},{"key":"10.1016\/j.medcli.2019.07.026_bib0335","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jtho.2018.03.031","article-title":"Safety and efficacy of PD-1 inhibitors among HIV-positive patients with non\u2013small cell lung cancer","volume":"13","author":"Ostios-Garcia","year":"2018","journal-title":"J Thorac Oncol."},{"key":"10.1016\/j.medcli.2019.07.026_bib0340","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1124\/pr.116.012682","article-title":"Targeting immune checkpoints in hematologic malignancies","volume":"68","author":"Alatrash","year":"2016","journal-title":"Pharmacol Rev."},{"key":"10.1016\/j.medcli.2019.07.026_bib0345","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2019.07.026_bib0350","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/cid\/ciy152","article-title":"Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells","volume":"67","author":"Park","year":"2018","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.medcli.2019.07.026_bib0355","doi-asserted-by":"crossref","first-page":"e397","DOI":"10.3324\/haematol.2017.164285","article-title":"Ibrutinib may impair serological responses to influenza vaccination","volume":"102","author":"Douglas","year":"2017","journal-title":"Haematologica."},{"key":"10.1016\/j.medcli.2019.07.026_bib0360","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/bjh.14855","article-title":"Lack of adequate pneumococcal vaccination response in chronic lymphocytic leukaemia patients receiving ibrutinib","volume":"182","author":"Andrick","year":"2018","journal-title":"Br J Haematol."},{"key":"10.1016\/j.medcli.2019.07.026_bib0365","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.4269\/ajtmh.16-0458","article-title":"Imported disease screening prior to chemotherapy and bone marrow transplantation for oncohematological malignancies","volume":"95","author":"S\u00e1nchez-Montalv\u00e1","year":"2016","journal-title":"Am J Trop Med Hyg."},{"key":"10.1016\/j.medcli.2019.07.026_bib0370","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1093\/cid\/cit071","article-title":"Has the time come for routine trimethoprim-sulfamethoxazole prophylaxis in patients taking biologic therapies?","volume":"56","author":"Bodro","year":"2013","journal-title":"Clin Infect Dis."}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775319306396?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775319306396?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T04:48:05Z","timestamp":1580100485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775319306396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0025775319306396"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2019.07.026","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Riesgo de infecci\u00f3n asociada a nuevas terapias para el tratamiento de los s\u00edndromes linfoproliferativos","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2019.07.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}